Most notably, we found that TP53 status can be further stratified by other gene expression signatures in addition to HRD to identify individuals with poor outcomes during treatment with combination palbociclib therapy and ET among both HR+/HER2− and HR+/HER+ breast cancers after progression on first-line ET. The gene discussed is ERBB2; the disease is breast carcinoma.